Sawabu N, Toya D, Takemori Y, Hattori N, Fukui M
Int J Cancer. 1986 May 15;37(5):693-6. doi: 10.1002/ijc.2910370509.
DU-PAN-2 is a high-molecular-weight glycoprotein defined by a murine monoclonal antibody (MAb) against a pancreatic ductal adenocarcinoma cell line. In order to evaluate the usefulness of this antigen as a tumor marker, we determined the serum level of the antigen by competitive inhibition radioimmunoassay in sera from 139 patients with various malignant tumors, chiefly digestive cancers, 98 patients with different benign diseases and 11 healthy subjects. Values in the healthy subjects were less than 100 U/ml. Levels above 100 U/ml were frequently observed in sera from benign diseases, but levels above 400 U/ml were found in only 6 of the patients with benign diseases. In contrast, levels exceeding 400 U/ml were detected in 72% of patients with pancreatic cancer, 44% of patients with hepatocellular cancer and 40% of patients with biliary tract cancer. The positivity was low in other cancers such as gastric cancer (19%) and colorectal cancer (7%). Serum levels of CEA and CA 19-9 were also determined in cancer patients. Among the pancreatic cancer patients studied, values above 400 U/ml were found in 5 of the 8 CEA-negative patients (less than 5 ng/ml) and 2 of the 3 CA 19-9 negative patients (less than 37 U/ml). These results indicate that determination of the serum DU-PAN-2 can aid in serological diagnosis of cancer of the digestive tract, more particularly of the pancreas.
DU-PAN-2是一种高分子量糖蛋白，由针对胰腺导管腺癌细胞系的鼠单克隆抗体（MAb）所界定。为评估该抗原作为肿瘤标志物的效用，我们采用竞争性抑制放射免疫分析法测定了139例患有各种恶性肿瘤（主要是消化道癌症）的患者、98例患有不同良性疾病的患者以及11名健康受试者血清中该抗原的水平。健康受试者的值低于100 U/ml。良性疾病患者的血清中经常观察到高于100 U/ml的水平，但只有6例良性疾病患者的血清中发现高于400 U/ml的水平。相比之下，72%的胰腺癌患者、44%的肝细胞癌患者和40%的胆管癌患者检测到超过400 U/ml的水平。在其他癌症如胃癌（19%）和结直肠癌（7%）中阳性率较低。还测定了癌症患者血清中癌胚抗原（CEA）和糖类抗原19-9（CA 19-9）的水平。在所研究的胰腺癌患者中，8例CEA阴性患者（低于5 ng/ml）中有5例、3例CA 19-9阴性患者（低于37 U/ml）中有2例的值高于400 U/ml。这些结果表明，测定血清DU-PAN-2有助于消化道癌症，尤其是胰腺癌的血清学诊断。
